References

Risk factors and mortality rates of carbapenem-resistant Gram-negative bacterial infections in intensive care units

10.1016/j.jointm.2023.11.007 · 2024 · External reference

Predictors of mortality in patients with infections due to multi-drug resistant gram negative bacteria: the study, the patient, the bug or the drug?

10.1016/j.jinf.2012.10.028 · 2013 · External reference

Increasing incidence of hospital-acquired and healthcare-associated bacteremia in Northeast Thailand: a multicenter surveillance study

10.1371/journal.pone.0109324 · 2014 · External reference

Risk assessment for antibiotic resistance in South East Asia

2017 · External reference

Epidemiology and burden of multidrug-resistant bacterial infection in a developing country

10.7554/elife.18082 · 2016 · External reference

Global priority list of antibiotic-resistant bacteria to guide research

2017 · External reference

Colistin monotherapy versus combination therapy for carbapenem-resistant organisms

10.1056/evidoa2200131 · 2023 · External reference

Multidrug-resistant Acinetobacter baumannii infection in children

10.1136/bcr.02.2011.3807 · 2011 · External reference

Intravenous colistin use for multidrug-resistant gram-negative infections in pediatric patients

10.5152/balkanmedj.2016.16210 · 2016 · External reference

Chapter six - side effects of antibiotics and perturbations of mitochondria functions

2023 · External reference

Antimicrobial susceptibility among colistin, Sulbactam, and Fosfomycin and a synergism Study of colistin in combination with Sulbactam or Fosfomycin against clinical isolates of carbapenem-resistant Acinetobacter baumannii

2018 · External reference

Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance

10.1016/j.jmii.2016.12.008 · 2017 · External reference

In vitro evaluation of the Colistin-Carbapenem combination in clinical isolates of A. baumannii using the checkerboard, etest, and time-kill curve techniques

10.3389/fcimb.2017.00209 · 2017 · External reference

Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology

10.1086/528867 · 2008 · External reference

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

10.1111/j.1469-0691.2011.03570.x · 2012 · External reference

Multidrug-resistant gram-negative bacteria: infection prevention and control update

2021 · External reference

Unresolved reference

2017 · External reference

Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study

10.1016/j.ijid.2021.06.052 · 2021 · External reference

Leucocytosis

2024 · External reference

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

10.2146/ajhp080434 · 2009 · External reference

KDIGO Clinical Practice guidelines for acute kidney injury

10.1159/000339789 · 2012 · External reference

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

10.1002/sim.3697 · 2009 · External reference

Prospective, comparative clinical study between high-dose colistin monotherapy and colistin–meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae

10.1016/j.jgar.2018.07.003 · 2018 · External reference

Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints

10.1128/jcm.02697-14 · 2015 · External reference

Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections

10.1128/aac.02435-13 · 2014 · External reference

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

10.1016/s1473-3099(18)30099-9 · 2018 · External reference

Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence

10.1128/aac.01222-13 · 2014 · External reference

Dose optimization of Colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an In Vitro Pharmacokinetic/Pharmacodynamic model

10.1128/aac.01989-18 · 2019 · External reference

Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: a systematic review and meta-analysis

10.1016/j.ijantimicag.2018.10.020 · 2019 · External reference

Physiologically-based pharmacokinetic modeling to inform dosing regimens and routes of administration of rifampicin and colistin combination against Acinetobacter baumannii

10.1016/j.ejps.2023.106443 · 2023 · External reference